CD4 T-cell exhaustion: does it exist and what are its roles in cancer?
In chronic infections and in cancer, persistent antigen stimulation under suboptimal
conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are …
conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are …
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
C Quartermaine, SM Ghazi, A Yasin, FT Awan… - Cardio Oncology, 2023 - jacc.org
Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …
[HTML][HTML] Small molecule-based immunomodulators for cancer therapy
Y Wu, Z Yang, K Cheng, H Bi, J Chen - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Immunotherapy has led to a paradigm shift in the treatment of cancer. Current cancer
immunotherapies are mostly antibody-based, thus possessing advantages in regard to …
immunotherapies are mostly antibody-based, thus possessing advantages in regard to …
[HTML][HTML] Targeting the tumor microenvironment in chronic lymphocytic leukemia
R Svanberg, S Janum, PEM Patten, AG Ramsay… - …, 2021 - ncbi.nlm.nih.gov
The tumor microenvironment (TME) plays an essential role in the development, growth, and
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …
[HTML][HTML] Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia
V Griggio, F Perutelli, C Salvetti, E Boccellato… - Frontiers in …, 2020 - frontiersin.org
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …
Cytotoxicity of the CD3× CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
M Mhibik, EM Gaglione, D Eik, J Herrick, J Le… - Blood …, 2023 - ashpublications.org
Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by
increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted …
increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted …
[HTML][HTML] Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets–beyond B lymphocytes
S Zhu, S Gokhale, J Jung, E Spirollari, J Tsai… - Frontiers in cell and …, 2021 - frontiersin.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
[HTML][HTML] The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
R Ramchandren, P Johnson, N Ghosh, J Ruan… - …, 2023 - thelancet.com
Background This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the
combination of ibrutinib, lenalidomide, and rituximab (iR 2 regimen) in patients with …
combination of ibrutinib, lenalidomide, and rituximab (iR 2 regimen) in patients with …
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
C Moreno, IG Solman, CS Tam, A Grigg… - Blood …, 2023 - ashpublications.org
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who
received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax …
received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax …
[HTML][HTML] Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
K Maharaj, A Uriepero, E Sahakian… - Frontiers in …, 2022 - frontiersin.org
Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by
controlling immune responses. They can be characterized by concomitant expression of …
controlling immune responses. They can be characterized by concomitant expression of …